



# Rinvoq in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

IMMUNOLOGY · JAK1 INHIBITOR

## The clinical situation

Rinvoq (upadacitinib) is an FDA-approved oral selective JAK1 inhibitor indicated across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, Crohn disease, and giant-cell arteritis. Manufactured by AbbVie. Standard dosing ranges from 15 to 45 mg once daily by indication; ambient-storage oral extended-release tablet with class boxed warning for serious infections, malignancy, MACE, thrombosis, and mortality.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating rheumatologist, dermatologist, or gastroenterologist documents diagnosis, prior biologic/JAK exposure, TB/HBV/HCV/herpes-zoster screening, and eligibility.
- 2 Treating centre confirmed.** A Saudi tertiary centre in Riyadh, Jeddah, or Dhahran accepts the case.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, and product details are filed; SFDA NPP electronic submission.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-temperature shipment.
- 5 Arrival & administration.** Patient begins once-daily dosing under physician monitoring; disease activity, CBC, LFTs, and lipids rechecked per label.

### Indicative economics

**Reference US cash-pay range:** USD 5,500–6,500 per 30-day supply. SFDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Ambient-temperature shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Rinvoq × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/rinvoq-saudi-arabia.html](https://reservemed.com/access-guides/rinvoq-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team